Noble Financial Remains a Buy on Oncology Institute (TOI)

Tip Ranks
2025.11.14 14:16
portai
I'm PortAI, I can summarize articles.

Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Oncology Institute with a price target of $8.00. Despite LeBoyer's average return of -9.2% and a 28.57% success rate, Oncology Institute also received a Buy rating from BTIG's David Larsen. However, TR | OpenAI – 4o maintained a Hold rating on the stock.

Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Oncology Institute today and set a price target of $8.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

According to TipRanks, LeBoyer is an analyst with an average return of -9.2% and a 28.57% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Gyre Therapeutics, Unicycive Therapeutics, and Ocugen.

In addition to Noble Financial, Oncology Institute also received a Buy from BTIG’s David Larsen in a report issued yesterday. However, today, TR | OpenAI – 4o reiterated a Hold rating on Oncology Institute (NASDAQ: TOI).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.